May 25, 2022
COMPASS LTOLE supports dual pathway inhibition for vascular protection
PHRI’s COMPASS Long Term Open Label Extension (LTOLE) “further highlights and supports long-term use of [Factor Xa inhibitor anticoagulant] rivaroxaban,...
Read More